Sonus completes phase-one trials

Article

Ultrasound contrast agent developerSonus Pharmaceuticals announced this month that its EchoGen agenthas completed phase-one clinical trials. Sonus, of Bothell, WA,made the announcement at the Alex. Brown & Sons Medical Conferencein Baltimore.

Ultrasound contrast agent developerSonus Pharmaceuticals announced this month that its EchoGen agenthas completed phase-one clinical trials. Sonus, of Bothell, WA,made the announcement at the Alex. Brown & Sons Medical Conferencein Baltimore.

EchoGen is the first agent in the Sonus pipeline. It is basedon an emulsion that turns into echogenic microbubbles when injected(SCAN 1/19/94).

The phase-one trial involved administration of EchoGen to 25healthy male subjects and obtaining blood samples to measure drugcontent and to detect potential safety parameters over a 72-hourperiod.

EchoGen appeared safe under the conditions of the study andthe drug was cleared from the body quickly after images were obtained,according to Sonus president and CEO Dr. Steven C. Quay.

In addition, EchoGen provided diagnostically useful informationabout heart, kidney and liver function and the vascular systemin 88% of the subjects in the study. Sonus will use the resultsof the study to develop phase-two clinical trials for EchoGenin cardiology and radiology, as well as an exercise-stress echocardiologystudy for myocardial perfusion.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.